New Alzheimer’s treatments: how to play the odds for Blarcamesine and Lecanemab — our hope and frustration
<p>If you read my past articles, you know that Anavex Life Sciences has had some seemingly very successful drug trials for its new Alzheimer’s drug, <strong>Blarcamesine</strong>. The drug, which comes in a pill form (this is important), seems not only to slow the progression of Alzheimer’s among the trial patients in general, but it seems to have a very outsized effect on a select group of patients (the super-responders).</p>
<p>Anavex Life Sciences just hosted a quarterly corporate conference call on its pharmaceutical work and its financial situation. Here’s the update on Blarcamesine:</p>
<p><a href="https://medium.com/@irwinbooks/new-alzheimers-treatments-how-to-play-the-odds-for-blarcamesine-and-lecanemab-our-hope-and-c35eafbab366"><strong>Read More</strong></a></p>